Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 22 of 760 for:    Area Under Curve AND Bioavailability

Bioavailability Study of Donepezil Hydrochloride Tablets 23 mg Under Fed Condition

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01923259
Recruitment Status : Completed
First Posted : August 15, 2013
Last Update Posted : August 15, 2013
Sponsor:
Information provided by (Responsible Party):
Dr. Reddy's Laboratories Limited

Brief Summary:
To evaluate and compare the relative bioavailability and therefore the bioequivalence of two different formulations of donepezil after a single oral dose administration under fed conditions.

Condition or disease Intervention/treatment Phase
Healthy Drug: Donepezil Phase 1

Detailed Description:
Single center, randomized, single dose, laboratory-blinded, 2-period, 2-sequence, crossover study under fed conditions.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 94 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Single Dose Crossover Comparative Bioavailability Study of Donepezil 23 mg Tablets in Healthy Male and Female Volunteers / Fed State
Study Start Date : October 2010
Actual Primary Completion Date : October 2010
Actual Study Completion Date : December 2010

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Donepezil Hydrochloride Tablets, 23 mg
Donepezil Hydrochloride Tablets, 23 mg of Dr.Reddy's Laboratories Ltd
Drug: Donepezil
Donepezil Hydrochloride tablets,23 mg
Other Name: Aricept

Active Comparator: Aricept
Aricept® 23 mg tablet of Eisai Inc
Drug: Donepezil
Donepezil Hydrochloride tablets,23 mg
Other Name: Aricept




Primary Outcome Measures :
  1. Area under curve (AUC) [ Time Frame: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 18, 24, 48 and 72 hours ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male or female volunteer
  2. Volunteer aged of at least 18 years but not older than 45 years
  3. Volunteer with a body mass index (BMI) greater than or equal to 21 and below 30 kg/m2
  4. Volunteer with a body weight greater than or equal to 60 kg.
  5. Light-, non- or ex-smokers. A light smoker is defined as someone smoking 10 cigarettes or less per day for at least 3 months before day 1 of this study. An ex-smoker is defined as someone who completely stopped smoking for at least 12 months before day 1 of this study.
  6. Availability for the entire study period
  7. Motivated volunteer and absence of intellectual problems likely to limit the validity of consent to participate in the study or the compliance with protocol requirements; ability to cooperate adequately; ability to understand and observe the instructions of the physician or designee.
  8. Clinical laboratory values within the laboratory's stated normal range; if not within this range, they must be without any clinical significance
  9. Have no clinically significant diseases captured in the medical history or evidence of clinically significant findings on physical examination and/or clinical laboratory evaluations (hematology, biochemistry, ECG and urinalysis)
  10. Willingness to adhere to the protocol requirements as evidenced by the informed consent form (ICF) duly read, signed and dated by the volunteer

Exclusion Criteria

  1. Seated pulse rate less than 50 bpm at screening
  2. Seated blood pressure below 105/60 mmHg at screening
  3. Seated blood pressure below 105/60 mmHg before drug administration
  4. Females who are pregnant or are lactating
  5. Females of childbearing potential who refuse to use an acceptable contraceptive regimen throughout the entire duration of the study
  6. History of significant hypersensitivity to donepezil, piperidine derivatives, scopolamine, or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs
  7. Presence of significant gastrointestinal, liver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects
  8. History of significant gastrointestinal, liver or kidney disease that may affect drug bioavailability
  9. Presence of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic or dermatologic disease
  10. Suicidal tendency, history of or disposition to seizures, state of confusion,clinically relevant psychiatric diseases
  11. Presence of out-of-range cardiac interval (PR < 110 msec, PR > 200 msec, QRS >110 msec and QTc > 440 msec) on the screening ECG or other clinically significant ECG abnormalities.
  12. Use of ASA or NSAIDs (or any product containing ASA or NSAIDs) in the previous 7 days before day 1 of this study
  13. Use of diphenhydramine in the previous 10 hours before day 1 of this study
  14. Known presence of rare hereditary problems of galactose and /or lactose intolerance
  15. Known presence of glaucoma or a predisposition to angle-closure glaucoma
  16. Maintenance therapy with any drug, or significant history of drug dependency or alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic)
  17. Any clinically significant illness in the previous 28 days before day 1 of this study
  18. Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450 (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem and HIV antivirals) and strong inducers of CYP enzymes (such as barbiturates, carbamazepine, glucocorticoids, phenytoin, rifampin and St John's Wort), in the previous 28 days before day 1 of this study
  19. Any history of tuberculosis and/or prophylaxis for tuberculosis
  20. Positive urine screening of alcohol and/or drugs of abuse
  21. Positive results to HIV, HBsAg or anti-HCV tests
  22. Females who are pregnant according to a positive serum pregnancy test
  23. Volunteers who took an Investigational Product (in another clinical trial) or donated 50 mL or more of blood in the previous 28 days before day 1 of this study.
  24. Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical studies, etc.) in the previous 56 days before day 1 of this study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01923259


Locations
Layout table for location information
Canada, Quebec
Algorithme Pharma Inc.
Mount Royal, Quebec, Canada, H3P 3P1
Sponsors and Collaborators
Dr. Reddy's Laboratories Limited
Investigators
Layout table for investigator information
Principal Investigator: Eric Sicard, MD Algorithme Pharma Inc

Layout table for additonal information
Responsible Party: Dr. Reddy's Laboratories Limited
ClinicalTrials.gov Identifier: NCT01923259     History of Changes
Other Study ID Numbers: DNI-P0-653
First Posted: August 15, 2013    Key Record Dates
Last Update Posted: August 15, 2013
Last Verified: February 2011
Additional relevant MeSH terms:
Layout table for MeSH terms
Donepezil
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Nootropic Agents